E. Koltun

发表

The design, synthesis, and biological evaluation of PIM kinase inhibitors.

Wei Xu, J. Nuss, Wentao Zhang, 2012, Bioorganic & medicinal chemistry letters.

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.

J. Martini, J. Nuss, Wentao Zhang, 2012, Bioorganic & medicinal chemistry letters.

Tartaric Acid and Tartrates in the Synthesis of Bioactive Molecules.

Arun K. Ghosh, G. Bilcer, E. Koltun, 2001, Synthesis.

Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment

M. Goldsmith, Mallika Singh, R. Nichols, 2020, Cancer Research.

Discovery of XL413, a potent and selective CDC7 inhibitor.

Wei Xu, Charles R. Holst, J. Nuss, 2012, Bioorganic & medicinal chemistry letters.

Regio- and Stereoselective Preparation of 3-Trimethylsilylallylic Alcohols by Solvolysis of 2-Trimethylsilylic Derivatives of 1-Bromo- and 1,1-Dibromocyclo-propanes in the Presence of CuSO4

O. Korneva, O. M. Nefedov, L. Menchikov, 1995 .

Discovery of a new class of glucosylceramide synthase inhibitors.

J. Nuss, S. Richards, P. Lamb, 2011, Bioorganic & medicinal chemistry letters.

Discovery and characterization of an inhibitor of glucosylceramide synthase.

K. Ogilvie, J. Nuss, S. Richards, 2012, Journal of medicinal chemistry.

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).

J. Martini, J. Nuss, Joerg Bussenius, 2012, ACS medicinal chemistry letters.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

G. Kiss, M. Goldsmith, Mallika Singh, 2018, Nature Cell Biology.

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss

G. Kiss, M. Goldsmith, Mallika Singh, 2017, bioRxiv.

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Mallika Singh, A. Gill, W. C. Gustafson, 2022, Cancer Research.

Abstract 1261: A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibition

Mallika Singh, R. Nichols, A. Gill, 2021, Experimental and Molecular Therapeutics.

Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers

Mallika Singh, A. Gill, J. Knox, 2022, Cancer Research.

Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models

Mallika Singh, A. Gill, C. Weller, 2022, Cancer Research.

Abstract 3598: A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13Cand drives tumor regressions in preclinical models

Mallika Singh, A. Gill, J. Knox, 2022, Cancer Research.

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Mallika Singh, R. Nichols, Y. Pourfarjam, 2023, Science.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

G. Kiss, M. Goldsmith, Mallika Singh, 2018, Nature Cell Biology.

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

C. Der, M. Rees, Y. Gindin, 2024, Nature.

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Y. Gindin, Adrian L Gill, K. Arbour, 2024, Cancer discovery.